parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.02 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in myonuclei	0.75
chemistry Open Targets	hard to drug	0.24
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	8 Parkinson's papers of 193	0.71
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 8250

receipt 8259: USP13 in dopamine neurons, braak

power: full sample -0.03 (p 0.894, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.09 (p 0.728, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.08 (p 0.748, n 18). could be the mix.
skeptic: leave-one-out range -0.16 to +0.08, sign flips 5; without severely affected donors -0.03 (p 0.894, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for USP13 in dopamine neurons.

case closed: nothing better to follow up.

receipt 8258: USP13 in oligodendrocytes, braak

power: full sample -0.13 (p 0.621, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.13 (p 0.621, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.23 (p 0.360, n 18). could be the mix.
skeptic: leave-one-out range -0.26 to -0.02, sign flips 0; without severely affected donors -0.13 (p 0.621, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for USP13 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts